Headache News

ACP released new clinical guidance on outpatient treatment of acute episodic migraine with combination therapy in patients who are not pregnant or lactating in outpatient settings.

WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.

People diagnosed with headache had a greater risk for attempting and completing suicide, according to results of a cohort study published in JAMA Neurology.

The ACP issued new clinical guidance on preventing episodic migraines, classified as one to 14 headache days per month, in nonpregnant or nonlactating adults in outpatient settings.

In three clinical trials, treatment with atogepant relieved migraine symptoms as soon as day 1, with consistent reductions through 4 weeks compared with placebo, according to research published in Neurology.

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.

Headache is one of the most common complaints seen by health care providers. There are various types of primary headache disorders, with the most common being migraine, tension headache and cluster headache.

Younger and middle-aged adults were more often affected by neurologic symptoms of long COVID than their older counterparts, regardless of how severe their initial infection was, data in Annals of Neurology show.

Affecting more than 1 billion people worldwide, migraine is among the most common neurological diseases. During their lives, 43% of women and 18% of men develop migraine.